Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

372
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
372
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

71
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
71
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

77
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
77
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model01:14

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

87
The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A...
87
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

129
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
129
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

78
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
78

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hysteretic Conductance in Ion Channel Gating.

Entropy (Basel, Switzerland)·2026
Same author

Development and Implementation of a Hinderance-based In Vitro Model for Porous Membranes.

The AAPS journal·2026
Same author

Dataset of xenobiotics human renal clearance values.

Database : the journal of biological databases and curation·2026
Same author

Virtual Bioequivalence Assessment of Long-acting Injectable Suspensions Using PBPK Modeling: Part 1. Impact of particle Size on Formulation Variability.

The AAPS journal·2026
Same author

Evaluating the Impact of Intestinal Bile Salts on Drug Absorption Using PBPK Modeling: Case Studies With Efavirenz, Cinnarizine, and Posaconazole.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Mechanistic Modelling of Lidocaine and Prilocaine Absorption from EMLA Cream upon Topical Application using Physiologically Based Pharmacokinetic Modelling.

AAPS PharmSciTech·2025
Same journal

RETRACTED: Meligy et al. Therapeutic Potential of Mesenchymal Stem Cells Versus Omega n - 3 Polyunsaturated Fatty Acids on Gentamicin-Induced Cardiac Degeneration. <i>Pharmaceutics</i> 2022, <i>14</i>, 1322.

Pharmaceutics·2026
Same journal

Correction: Mohite et al. Bioactive Compound-Fortified Nanomedicine in the Modulation of Reactive Oxygen Species and Enhancement of the Wound Healing Process: A Review. <i>Pharmaceutics</i> 2025, <i>17</i>, 855.

Pharmaceutics·2026
Same journal

Metal Nanoparticle-Reinforced Hydrogels Applied in the Inhibition of Clinical Pathogens: Structural Features, Mechanisms, and Biomedical Prospects.

Pharmaceutics·2026
Same journal

Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Cipepofol Across Diverse Clinical Populations.

Pharmaceutics·2026
Same journal

Artificial Intelligence in Nanopharmaceutical Development: From Predictive Design to Clinical Translation.

Pharmaceutics·2026
Same journal

Textilinin-1, a Snake Venom-Derived Kunitz-Type Protease Inhibitor, Accelerates Wound Healing Through Anti-Inflammatory, Antibacterial, and Pro-Regenerative Activities.

Pharmaceutics·2026
See all related articles

Related Experiment Video

Updated: Mar 29, 2026

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
07:41

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0

Published on: June 5, 2017

10.4K

Exploring Tafamidis Effects Through PBPK-QSP Modelling.

Seweryn Ulaszek1,2, Bartek Lisowski1, Barbara Wiśniowska3

  • 1Chair of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.

Pharmaceutics
|March 28, 2026
PubMed
Summary
This summary is machine-generated.

Tafamidis increases transthyretin (TTR) levels by reducing TTR clearance, not synthesis. This PBPK-QSP model supports reduced clearance of stabilized TTR as the mechanism, with dose adjustments based on baseline TTR levels.

Keywords:
physiologically based pharmacokineticsquantitative systems pharmacologytafamidistransthyretin

More Related Videos

Microfluidic On-chip Capture-cycloaddition Reaction to Reversibly Immobilize Small Molecules or Multi-component Structures for Biosensor Applications
14:43

Microfluidic On-chip Capture-cycloaddition Reaction to Reversibly Immobilize Small Molecules or Multi-component Structures for Biosensor Applications

Published on: September 23, 2013

11.3K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K

Related Experiment Videos

Last Updated: Mar 29, 2026

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0
07:41

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0

Published on: June 5, 2017

10.4K
Microfluidic On-chip Capture-cycloaddition Reaction to Reversibly Immobilize Small Molecules or Multi-component Structures for Biosensor Applications
14:43

Microfluidic On-chip Capture-cycloaddition Reaction to Reversibly Immobilize Small Molecules or Multi-component Structures for Biosensor Applications

Published on: September 23, 2013

11.3K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Systems Pharmacology Modeling
  • Drug Metabolism and Transport

Background:

  • Tafamidis, a transthyretin kinetic stabilizer, is known to increase circulating transthyretin (TTR) levels.
  • The precise mechanism driving this TTR level increase remains incompletely understood.
  • Understanding the TTR dynamics is crucial for optimizing tafamidis therapy.

Purpose of the Study:

  • To evaluate the performance of a physiologically based pharmacokinetic (PBPK) model for tafamidis.
  • To calibrate a quantitative systems pharmacology (QSP) model to explore mechanistic hypotheses of TTR dynamics.
  • To investigate the dose-response relationship for tafamidis-induced TTR increases.

Main Methods:

  • Construction of an integrated PBPK-QSP model in Simcyp using LUA modules.
  • Parameterization and validation of the PBPK component against clinical pharmacokinetic data.
  • Simulation of tafamidis-TTR binding kinetics, stabilization, and clearance in virtual healthy subjects.

Main Results:

  • The PBPK model accurately predicted tafamidis exposure (AUC, Cmax) within a 1.3-fold range.
  • The integrated model reproduced the observed 33% TTR increase, supporting reduced clearance of stabilized TTR.
  • Simulations suggest dose-sensitivity, with lower baseline TTR potentially requiring reduced doses for stabilization.

Conclusions:

  • The developed PBPK-QSP model successfully reproduces tafamidis pharmacokinetics and TTR responses.
  • A plausible mechanistic hypothesis involves clearance modulation of stabilized TTR, not altered TTR synthesis.
  • The model provides a framework for understanding tafamidis's clinical effects and guiding dose optimization.